Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III.

J Thromb Thrombolysis · 2025 · PMC11885355 · PMID 39924624

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Consistent with our study, the ARISTOTLE trial demonstrated that apixaban significantly reduced the risk of major bleeding compared to VKA, but with a decreasing trend among patients with a CrCl of 25–50 ml/min [ 22 ].

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.